Suramin and radiotherapy in newly diagnosed glioblastoma: Phase 2 NABTT CNS Consortium study
Open Access
- 1 January 2004
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 6 (1) , 15-20
- https://doi.org/10.1215/s1152851703000127
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Phase III Study Comparing Three Cycles of Infusional Carmustine and Cisplatin Followed by Radiation Therapy With Radiation Therapy and Concurrent Carmustine in Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme: Eastern Cooperative Oncology Group Trial 2394Journal of Clinical Oncology, 2003
- Suramin is a Potent Inhibitor of Vascular Endothelial Growth Factor. A Contribution to the Molecular Basis of its Antiangiogenic ActionJournal of Molecular and Cellular Cardiology, 1996
- Suramin inhibits C6 glioma‐induced angiogenesis in vitroJournal of Cellular Biochemistry, 1995
- The Efficacy and Distribution of Suramin in the Treatment of the 9L GliosarcomaNeurosurgery, 1994
- Suramin inhibits glioma cell proliferationin vitro and in the brainJournal of Neuro-Oncology, 1994
- Suramin, an Active Drug for Prostate Cancer: Interim Observations in a Phase I TrialJNCI Journal of the National Cancer Institute, 1993
- Suramin, an anti‐cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2AFEBS Letters, 1989
- Transformation of NIH 3T3 cells with basic fibroblast growth factor or the hst/K-fgf oncogene causes downregulation of the fibroblast growth factor receptor: reversal of morphological transformation and restoration of receptor number by suramin.The Journal of cell biology, 1989
- Suramin inhibition of growth factor receptor binding and mitogenicity in AKR‐2B cellsJournal of Cellular Physiology, 1987
- Suramin binds to platelet‐derived growth factor and inhibits its biological activityJournal of Cellular Biochemistry, 1985